Download File - JOHN J. HADDAD, Ph.D.

106 Luptrawan et al.
30. Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by
transforming growth factor beta and reversal by recombinant tumor necrosis factor
alpha. J Exp Med 1987; 166:991–998.
31. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev
Immunol 1998; 16:137–161.
32. Smyth MJ, Strobl SL, Young HA, et al. Regulation of lymphokine-activated killer
activity and pore-forming protein gene expression in human peripheral blood CD8þ
T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol 1991;
146:3289–3297.
33. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during
tumor evasion of immune surveillance. Cancer Cell 2005; 8:369–380.
34. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated
immunosuppression. J Leukoc Biol 2005; 77:3–15.
35. Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits
antitumor immune responses in vitro. Neurosurgery 1995; 37:1160–1166; discussion
1166–1167.
36. Fiore E, Fusco C, Romero P, et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B)
proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural
killer cell-mediated cytotoxicity. Oncogene 2002; 21:5213–5223.
37. Schiltz PM, Gomez GG, Read SB, et al. Effects of IFN-gamma and interleukin-1beta
on major histocompatibility complex antigen and intercellular adhesion molecule-1
expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic
T lymphocytes. J Interferon Cytokine Res 2002; 22:1209–1216.
38. O’Connor GM, Hart OM, Gardiner CM. Putting the natural killer cell in its place.
Immunology 2006; 117:1–10.
39. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G
expression in human gliomas: an alternative strategy of immune escape. J Immunol
2002; 168:4772–4780.
40. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy
receptor for Fas ligand in lung and colon cancer. Nature 1998; 396:699–703.
41. Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by
malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Cancer Res 2001; 61:2759–2765.
42. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with
peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell
infiltration. Cancer Res 2001; 61:842–847.
43. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells
elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer
Res 2004; 64:4973–4979.
44. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination
of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol
Immunother 2001; 50:337–344.
45. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of
dendritic and glioma cells and recombinant human interleukin 12. J Immunother
(1997) 2004; 27:452–459.
46. Akasaki Y, Kikuchi T, Homma S, et al. Antitumor effect of immunizations with
fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother
2001; 24:106–113.